Väisänen V - Search Results

1

Time-resolved fluorescence imaging for quantitative histochemistry using lanthanide chelates in nanoparticles and conjugated to monoclonal antibodies.

Väisänen V, Härmä H, Lilja H, Bjartell A. Väisänen V, et al. Luminescence. 2000 Nov-Dec;15(6):389-97. doi: 10.1002/1522-7243(200011/12)15:6<389::AID-BIO626>3.0.CO;2-7. Luminescence. 2000. PMID: 11114116

2

Development of sensitive immunoassays for free and total human glandular kallikrein 2.

Väisänen V, Eriksson S, Ivaska KK, Lilja H, Nurmi M, Pettersson K. Väisänen V, et al. Clin Chem. 2004 Sep;50(9):1607-17. doi: 10.1373/clinchem.2004.035253. Epub 2004 Jul 9. Clin Chem. 2004. PMID: 15247158 Free article.

3

Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments.

Väisänen V, Peltola MT, Lilja H, Nurmi M, Pettersson K. Väisänen V, et al. Anal Chem. 2006 Nov 15;78(22):7809-15. doi: 10.1021/ac061201+. Anal Chem. 2006. PMID: 17105175

4

Studies on phenotypic expression patterns of proteases and protease inhibitors in benign compared to malignant prostate tissues.

Bjartell A, Paju A, Stenman UH, Väisänen V, Aumüller G, Diamandis E, Becker C, Lilja H. Bjartell A, et al. Among authors: vaisanen v. Prostate Cancer Prostatic Dis. 2000 Dec;3(S1):S7. doi: 10.1038/sj.pcan.4500431. Prostate Cancer Prostatic Dis. 2000. PMID: 12497117 No abstract available.

5

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.

Steuber T, Vickers AJ, Serio AM, Vaisanen V, Haese A, Pettersson K, Eastham JA, Scardino PT, Huland H, Lilja H. Steuber T, et al. Among authors: vaisanen v. Clin Chem. 2007 Feb;53(2):233-40. doi: 10.1373/clinchem.2006.074963. Epub 2006 Dec 21. Clin Chem. 2007. PMID: 17185368

6

Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA.

Nurmikko P, Väisänen V, Piironen T, Lindgren S, Lilja H, Pettersson K. Nurmikko P, et al. Among authors: vaisanen v. Clin Chem. 2000 Oct;46(10):1610-8. Clin Chem. 2000. PMID: 11017939

7

Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.

Haese A, Vaisanen V, Lilja H, Kattan MW, Rittenhouse HG, Pettersson K, Chan DW, Huland H, Sokoll LJ, Partin AW. Haese A, et al. Among authors: vaisanen v. J Urol. 2005 Mar;173(3):752-6. doi: 10.1097/01.ju.0000152618.38747.dd. J Urol. 2005. PMID: 15711262

8

Standardization of two immunoassays for human glandular kallikrein 2.

Haese A, Vaisanen V, Finlay JA, Pettersson K, Rittenhouse HG, Partin AW, Bruzek DJ, Sokoll LJ, Lilja H, Chan DW. Haese A, et al. Among authors: vaisanen v. Clin Chem. 2003 Apr;49(4):601-10. doi: 10.1373/49.4.601. Clin Chem. 2003. PMID: 12651813

9

Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells.

Väisänen V, Lövgren J, Hellman J, Piironen T, Lilja H, Pettersson K. Väisänen V, et al. Prostate Cancer Prostatic Dis. 1999 Mar;2(2):91-97. doi: 10.1038/sj.pcan.4500289. Prostate Cancer Prostatic Dis. 1999. PMID: 12496845

10

Free and total human glandular kallikrein 2 in patients with prostate cancer.

Väisänen V, Pettersson K, Alanen K, Viitanen T, Nurmi M. Väisänen V, et al. Urology. 2006 Jul;68(1):219-25. doi: 10.1016/j.urology.2006.01.075. Urology. 2006. PMID: 16844459

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters